Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$126.17 USD

126.17
312,945

+1.92 (1.55%)

Updated Sep 12, 2024 04:00 PM ET

After-Market: $126.25 +0.08 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Integer Holdings (ITGR) Q4 Earnings and Sales Beat, Margins Up

by Zacks Equity Research

Integer Holdings (ITGR) reports fourth-quarter results, with earnings and revenues beating their respective consensus marks.

Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

West Pharmaceutical (WST) Beats on Q4 Earnings, HVP Drives Sales

by Zacks Equity Research

West Pharmaceutical's (WST) fourth-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.

Masimo's (MASI) MightySat Pulse Oximeter Receives FDA Approval

by Zacks Equity Research

Masimo's (MASI) MightySat Medical Pulse Oximeter receives FDA clearance, which makes it the first FDA-approved pulse oximeter to be available OTC.

Veeva (VEEV) & Boehringer Partner to Boost Animal Healthcare

by Zacks Equity Research

Veeva (VEEV) collaborates with Boehringer to offer its Veeva Vault Clinical and Veeva Vault RIM applications to improve animals??? healthcare via technological upliftment.

Compared to Estimates, Integer (ITGR) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Integer (ITGR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Edwards (EW) Gains From Balanced Core Growth and New Launches

by Zacks Equity Research

Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.

Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi

by Zacks Equity Research

Tandem's (TNDM) Mobi is claimed to be the world's smallest durable automated insulin delivery system.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High With More Upside Potential

by Vasundhara Sawalka

Investors target stocks that have lately been on a bull run. Stocks like SUN, ITGR, DB and LRN are seeing price strength and have a high chance of carrying the momentum forward.

QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall

by Zacks Equity Research

Despite solid performances by the Labs segment and China and Other regions, QuidelOrtho (QDEL) misses earnings and revenue estimates by 41.8% and 6.9%, respectively.

Debanjana Dey headshot

Medical Products Stocks' Earnings Due on Feb 15: WST, ITGR & More

by Debanjana Dey

Medical Products companies' quarterly results are likely to reflect strength in customer demand. Let's see how ITGR, WST, AMN and PACB are placed ahead of their earnings releases.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

CVS Health (CVS) Gains From Digital Adoption Amid Competition

by Zacks Equity Research

CVS Health (CVS) has been removing barriers to digital adoption and making it easier for customers to access services such as pharmacy refills and advanced scheduling for immunizations online.

GE Healthcare (GEHC), MedQuest Partner to Boost Imaging Field

by Zacks Equity Research

GE Healthcare (GEHC) collaborates with MedQuest to optimize outpatient imaging networks. With AI capabilities from GE Healthcare, MedQuest is likely to provide better solutions in the imaging space.

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device

by Zacks Equity Research

ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.

Globus Medical (GMED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cooper Companies (COO), Fulgent Unite to Boost Genetic Testing

by Zacks Equity Research

Cooper Companies (COO) collaborates with Fulgent Genetics to boost newborn genetic screenings. CBR by Cooper Surgical is likely to provide a variety of genetic testing options to its families.

Here's Why You Should Add HealthEquity (HQY) to Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Integer (ITGR) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Integer (ITGR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System

by Zacks Equity Research

Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.

DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand

by Zacks Equity Research

Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.

Here's Why You Should Invest in Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.